A Pure-Play Pivot: Surgery Partners Sheds Idaho Falls

Portfolio optimization reaches its apex as SGRY divests its most complex market to refocus on short-stay surgery and deleveraging.

SGRY · Earnings Call · 2026-08-10

The Landmark Divestiture

The second quarter of 2026 marked a defining moment for Surgery Partners. The company announced the signing of definitive agreements to sell its Idaho Falls market to Intermountain Health, a transaction that crystallizes a year-long strategic review. As CEO Eric Evans put it:

We have signed definitive agreements in escrow for the sale of our interest in the Idaho Falls market, Mountain View Hospital and Idaho Falls Community Hospital to our partner, Intermountain Health.
J. Evans, Chief Executive Officer · 2026-08-10

This move is the culmination of what the company has described as its portfolio optimization efforts. CFO Dave Doherty highlighted the financial implications: “This transaction represents the largest step in our portfolio optimization strategy, and it reinforces our commitment to streamlining the business...” — David Doherty, Chief Financial Officer · 2026-08-10 The company expects to receive $795 million in gross proceeds, valued at approximately 7x LTM adjusted EBITDA but closer to 17x the distributions actually received. The divestiture will reduce balance sheet leverage by about 0.3 turns.

The New, Simpler Company

Post-transaction, SGRY will be a pure-play short-stay surgical provider. This means significantly lower Medicaid exposure, no obstetrics or neonatology, and a majority reduction in non-surgical admissions. As Eric noted: “I would just remind everyone that really isn't a risk for us. purely elective business. Our Medicaid business actually post the pending transaction would be less than 2%.” — J. Evans, Chief Executive Officer · 2026-08-10 This simplification directly addresses the commercial mix pressure that has been a recurring theme. The company's go-forward portfolio will also have a dramatically smaller footprint in acute-care services, reducing exposure to emergency-department volatility and readmission penalties. The market has recognized this shift—the stock has rallied ~12% over the past 90 days, recovering from a deep drawdown.

Operational Discipline and Growth Drivers

Despite the mix shift, same-facility revenue grew 5% in the quarter, driven by higher acuity cases and rate. Physician recruiting remains a growth engine, with 191 new physicians joining in the quarter—the initial revenue contribution from the 2026 cohort is up nearly 16% versus last year. The company continues to invest in de novo development with six facilities under construction and a robust pipeline. Cost management remains a pillar; new COO Justin Oppenheimer is focused on labor, supplies, and systemic efficiencies. Operating expenses improved sequentially as a percentage of revenue, and the company expects further margin expansion.

Financial Trajectory and Outlook

The company reaffirmed full-year 2026 guidance (revenue of $3.35–3.45B, adjusted EBITDA ≥$530M), which excludes the Idaho Falls impact. Management expects to provide updated guidance promptly after closing, giving investors a cleaner view of the go-forward growth profile. The transaction is expected to improve cash conversion dramatically—the Idaho Falls facilities had capital expenditures of ~$17M annually and represented ~32% of total finance lease obligations. Effective net cash is -$3.4B as of Q1, and the sale will meaningfully dent this. The company's historical margin profile has been volatile, but the remaining portfolio is more homogenously focused on high-margin, outpatient procedures. Management's guidance implies a clear path toward its leverage target of sub-3x, down from the current 4.4x credit-agreement basis. This pivot is not a sudden move but a deliberate culmination. In the prior quarter, Eric said: “We remain committed to reviewing those opportunities within our portfolio...” — J. Evans, Chief Executive Officer · 2026-05-05 And in November 2025, he noted: “We are off and running on those processes.” — Eric Evans, CEO · 2025-11-10 The Idaho Falls sale is the most impactful step, and it signals that management is serious about simplifying the business, accelerating free-cash-flow growth, and rewarding shareholders through deleveraging. The market's positive reaction suggests investors are rewarding this strategic discipline.